More articles about: Blood Disorders (Hematology)

Elijah Dottery, diagnosed with sickle cell anemia as a baby, becomes the first U-M patient to receive the newly-approved FDA therapy which involves using mesenchymal stem cells.

Using one's cells to attack and treat cancer continues to grow. Cellular therapy and in particular CAR T-cell therapy offers new opportunities to adult and pediatric patients with blood cancers like leukemia and lymphoma. Dr. Monalisa Ghosh, Rogel Cancer Center oncologist talks about these treatments and and the future of cellular therapy.

The National Marrow Donor Program matches bone marrow donors with those who need it for cancer or blood disorder treatment. A University of Michigan Medical School graduate was able to give her marrow and a second chance at life to a young girl in Nebraska.

Here, Monalisa Ghosh, M.D., a hematologist-oncologist at the University of Michigan Health Rogel Cancer Center, answers questions about cellular therapy; how it's used and what exciting developments are soon to come.

A study builds on previous work that found depriving T cells of iron prevented cells from proliferating. The current study, published in PNAS, found that excess iron is just as problematic.

The FDA approved the use of a therapeutic device invented and developed at the University of Michigan for use in children with acute kidney injury and sepsis or a septic condition requiring continuous kidney replacement therapy.

Researchers at the University of Michigan Health have unveiled a new mechanism that drives thrombocytopenia and a potential clinically actionable biomarker for antiphospholipid syndrome associated thrombocytopenia.

Babies born with sickle cell disease face social inequality as well as a lifelong chronic disease that is often undertreated with proven drugs.

How two newly approved gene therapies, including novel technology CRISPR, may help kids and adults with inherited blood disorders

In a study of the three most commonly prescribed blood thinners, the oral anticoagulant rivaroxaban, known by the brand name Xarelto, was associated with a significantly higher risk of bleeding complications than apixaban (brand name Eliquis) and warfarin for patients with blood clots or atrial fibrillation.

Infants with hemophilia A who received monoclonal antibody emicizumab experienced few bleeding events and no serious complications, a study suggests.

University of Michigan Health Rogel Cancer Center scientists have found a potential solution for preventing a common and dangerous complication in patients that receive stem cell transplants from a donor’s blood or bone marrow.  

Research from experts at Michigan Medicine, the Children’s Hospital of Philadelphia and Penn Medicine is breaking ground on new ways of treating blood disorders, such as sickle cell anemia, through gene therapy.

A national study of blood ferritin and hemoglobin levels from tween, teen and young adult females suggests routine screening might be needed for iron deficiency and anemia

In 2011, Ruth was diagnosed with multiple myeloma. Understanding that it is an incurable disease, she puts her best foot forward by starting each day with gratitude, receiving her treatment, and staying healthy. She cherishes the opportunity it is to wake up each day and choose her inner strength. This is her story and advice to others.